Novo Nordisk, the Danish pharmaceutical company known for its blockbuster weight-loss medication Ozempic, is facing renewed investor scrutiny despite the recent commercial success of its oral semaglutide pill. Since the drug’s launch in the United States in January, more than 1.5 million people have begun using the daily tablet version of Wegovy, the injectable originally prescribed for obesity management, marking a significant scientific and commercial milestone for the company.
However, the optimism surrounding Novo Nordisk’s market performance has significantly waned. The company’s stock price has dropped approximately 70% from its peak in mid-2024, a period when Novo Nordisk was Europe’s most valuable publicly traded company. Investors have become increasingly cautious, particularly with the forthcoming expiration of a key U.S. patent on semaglutide anticipated early in the next decade, raising concerns over generic competition and revenue sustainability.
Despite recent announcements indicating that sales and profits will not decline as sharply as previously forecasted for this year, investor confidence remains subdued. Market participants are closely watching the intensifying competition from American pharmaceutical firms, notably Eli Lilly, which has expanded its own offerings in the obesity treatment sector.
Novo Nordisk’s chief executive officer, Mike Doustdar, has expressed that this investor apprehension overlooks the company’s broader pharmaceutical portfolio and ongoing drug development pipeline. In an interview, Doustdar emphasized that the firm's asset base extends well beyond its flagship semaglutide products. He suggested that the market undervalues the variety of therapeutic candidates under development, which address conditions beyond weight management, including cardiovascular and liver diseases.
The company’s efforts to diversify its product line and leverage semaglutide’s therapeutic potential in other medical areas reflect a strategic attempt to mitigate reliance on a single drug. Novo Nordisk, which historically gained acclaim for advancing treatments that deliver multifaceted health benefits, continues to pursue innovations in metabolic and chronic disease therapies.
As Novo Nordisk prepares for the patent expiration challenge, the firm’s ability to sustain growth will depend on both its innovation pipeline and competitive positioning within the expanding obesity treatment market. While investor caution persists, the pharmaceutical industry and healthcare providers remain attentive to the company’s next steps.